Business Wire

GN expands groundbreaking ReSound OMNIA family enabling more people to hear their best in noise

7.2.2023 11:00:00 EET | Business Wire | Press release

Share

GN Hearing, the global leader in hearing aid innovation, today announces the expansion of the popular ReSound OMNIA family, providing more options to address the biggest unmet need for people with hearing loss: hearing speech in noisy environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005021/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

GN expands groundbreaking ReSound OMNIA family enabling more people to hear their best in noise (Photo: Business Wire)

Despite hearing in noise being the main reason why people get hearing aids, 86% of people who wear them still struggle with speech understanding in noise.1 The launch will see GN Hearing expand the premium natural sound offering of ReSound OMNIA into more devices to match the needs and wants of a larger group of people. ReSound OMNIA provides an exceptional 150% improvement in speech understanding in noise2 and is the only hearing solution to simultaneously combine two benefits – narrow beamforming directionality for hearing in noise and omnidirectional listening for a natural listening experience without feeling cut off.2

The ReSound OMNIA technology is available in a full line-up of popular styles to cater to all hearing needs and preferences. In addition to the Receiver-in-Ear hardware launched in August 2022, the family now includes miniRIE, Behind-the-Ear (BTE) and custom-made styles to ensure even more people living with hearing loss will be able to access GN’s most advanced technology, and with greater listening comfort.

As part of the expansion, GN is launching their smallest rechargeable RIE yet, the miniRIE, for a stylish and cosmetic fit without compromising on sound quality. The miniRIE is designed for best wearing comfort, thanks to its size, shape and the soft curves. The device offers all day battery life for worry-free use throughout the day and without the hassle of exchanging fiddly batteries on the go.

GN Hearing CEO and President, Gitte Aabo explains, “Nobody should feel limited by noisy environments. I’m delighted that more people can now benefit from these new best-in-class hearing aids which will help improve hearing in noise without leaving anyone feeling cut off. People with hearing challenges can now strengthen their connections to people and the world around them and hear the sounds that matter.”

All solutions under the ReSound OMNIA family will provide enhanced connectivity, whether users are streaming phone calls or music to their ears. Users can answer calls with just a tap on their hearing aid and enjoy crystal-clear conversations with outstanding sound quality – all without having to take their smart phone out of their pocket.*

The extended ReSound OMNIA portfolio is planned for Regulatory clearance and will be available globally starting with the US and Canada on February 23, 2023, along with the equivalent Beltone Achieve line-up.

For more information, visit the ReSound website.

1 MarkeTrak 22, 2022

2 Jespersen et al (2022)

* ReSound OMNIA hands-free calls are compatible with iPhone 11 or later, iPad Pro 12.9-inch (5th generation), iPad Pro 11-inch (3rd generation), iPad Air (4th generation), and iPad mini (6th generation) or later, with software updates iOS 15.3 and iPadOS 15.3 or later.

- ENDS -

NOTES TO EDITORS

About GN Group

GN Group facilitates communication between people through its intelligent hearing, audio, video, and gaming technology. Inspired by people and driven by our innovation leadership, we leverage technological synergies to deliver unique and increasingly individualized user experiences in our products and solutions.

150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, audio, video and speech, wireless technologies, miniaturization, and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, SteelSeries, Jabra, Beltone, Interton, BlueParrott, Danavox and FalCom in around 100 countries. Founded in 1869, the GN Group employs 7,000 people and is listed on Nasdaq Copenhagen (GN.CO).

Visit our homepage GN.com and connect with us on LinkedIn and Facebook .

© 2023 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Beltone is a trademark of GN Hearing Care Corporation. Apple, the Apple logo, iPhone, iPad, and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information, please contact:

Press and the media
Aysel Cengiz
Director, Global PR & Communications
Tel: +45 2894 1821

Steen Frentz Laursen
Vice President, Corporate Communications
Tel: +45 45 75 07 21

Investors and analysts
Anne Sofie Staunsbæk Veyhe
Vice President, IR, Treasury and M&A
Tel: +45 45 75 85 06

Rune Sandager
Senior Director, Investor Relations
Tel: +45 45 75 92 57

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release

Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release

The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release

Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye